Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP232204.RAYEjCzVXQE4O82sNddBalGLbPzHMyHaSp7TOpeEhk9Pc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP232204.RAYEjCzVXQE4O82sNddBalGLbPzHMyHaSp7TOpeEhk9Pc130_assertion type Assertion NP232204.RAYEjCzVXQE4O82sNddBalGLbPzHMyHaSp7TOpeEhk9Pc130_head.
- NP232204.RAYEjCzVXQE4O82sNddBalGLbPzHMyHaSp7TOpeEhk9Pc130_assertion description "[We assess key issues in anti-angiogenic treatment including potential ways for addressing resistance; we review the current studies of PARP inhibitor treatment, which shows most promise in patients with germline BRCA mutations; we describe the potential for folate-receptor-directed therapy, given the high level of FR expression in ovarian cancer and we highlight the potential for molecular targeted therapy, focusing on specific subgroups of the disease with targets such as the PI3 K/AKT and RAS/RAF/MEK pathways and the ErbB family of oncogenes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP232204.RAYEjCzVXQE4O82sNddBalGLbPzHMyHaSp7TOpeEhk9Pc130_provenance.
- NP232204.RAYEjCzVXQE4O82sNddBalGLbPzHMyHaSp7TOpeEhk9Pc130_assertion evidence source_evidence_literature NP232204.RAYEjCzVXQE4O82sNddBalGLbPzHMyHaSp7TOpeEhk9Pc130_provenance.
- NP232204.RAYEjCzVXQE4O82sNddBalGLbPzHMyHaSp7TOpeEhk9Pc130_assertion SIO_000772 24265409 NP232204.RAYEjCzVXQE4O82sNddBalGLbPzHMyHaSp7TOpeEhk9Pc130_provenance.
- NP232204.RAYEjCzVXQE4O82sNddBalGLbPzHMyHaSp7TOpeEhk9Pc130_assertion wasDerivedFrom befree-20150227 NP232204.RAYEjCzVXQE4O82sNddBalGLbPzHMyHaSp7TOpeEhk9Pc130_provenance.
- NP232204.RAYEjCzVXQE4O82sNddBalGLbPzHMyHaSp7TOpeEhk9Pc130_assertion wasGeneratedBy ECO_0000203 NP232204.RAYEjCzVXQE4O82sNddBalGLbPzHMyHaSp7TOpeEhk9Pc130_provenance.